Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia.

Experimental hematology - 1 Dec 2008

Mossuz Pascal, Arlotto Marie, Hermouet Sylvie, Bouamrani Ali, Lippert Eric, Girodon François, Dobo Irène, Vincent Praloran, Cahn Jean Yves, Berger François

Abstract excerpt

OBJECTIVE: Previous studies have suggested that two subtypes of essential thrombocythemia (ET) could be separated on the basis of their JAK2 status (V617F-positive or V617F-negative), with a continuum between V617F-positive ET and polycythemia vera (PV). Nevertheless, increasingly contradictory data on the impact of JAK2-V617F (presence and load) on ET phenotype highlight the need for further investigations....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation, Missense
Share to Blood Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Diseases, Inborn

Share to Janus Kinase 2

Share to Polycythemia Vera

Share to Proteome

Share to Proteomics

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 18838204
DOI: 10.1016/j.exphem.2008.07.013

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia.PMID 18838204Read ↗

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.Semantic proximity Read ↗

High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.Semantic proximity Read ↗

JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients.Semantic proximity Read ↗

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.Semantic proximity Read ↗

Apolipoprotein A1: A new serum marker correlated to JAK2 V617F proportion at diagnosis in patients with polycythemia vera.Semantic proximity Read ↗

Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches.Semantic proximity Read ↗

JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.Semantic proximity Read ↗

Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia.Semantic proximity Read ↗

Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood.Semantic proximity Read ↗

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemiaSemantic proximity Read ↗

Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.